Companies Dominating the Vulvar And Vaginal Atrophy (Vva) Therapy Landscape
- Daré Bioscience, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Almirall, S.A.
- Viveve, Inc.
- Lutronic Corporation
- Venus Concept
- ThermiGen, LLC
- Alma Lasers LTD.
- BTL
- Fotona d.o.o.
- TherapeuticsMD, Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of vulvar and vaginal atrophy therapy is assessed at USD 2.9 billion.
The vulvar and vaginal atrophy therapy market size was over USD 2.46 billion in 2024 and is projected to reach USD 9.22 billion by 2037, growing at around 10.7% CAGR during the forecast period i.e., between 2025-2037. Increasing incidences of breast cancer and uterine cancer in women and the growing prevalence of UTI will boost the market growth.
North America industry is poised to hold largest revenue share by 2037, attributed to surge in the number of women suffering from pre and postmenopausal hormonal imbalances along with the growing number of vaginal cancer cases in the region.
The major players in the market are Daré Bioscience, Inc., Almirall, S.A., Viveve, Inc., Lutronic Corporation, Venus Concept, ThermiGen, LLC, Alma Lasers LTD., BTL, Fotona d.o.o., TherapeuticsMD, Inc, .
